Lv1
40 积分 2024-01-08 加入
Presence of myositis-specific autoantibodies may predict favourable outcomes to rituximab in patients with idiopathic inflammatory myositis: Retrospective observational study
13天前
已完结
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
10个月前
已完结
Real-life effectiveness of rituximab in different subsets of idiopathic inflammatory myopathies
10个月前
已关闭
皖公网安备34019202002308
